Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS105 combination therapy in advanced solid tumors
NCT06208410Phase 2Recruiting
- Sponsor
- Risen Pharma
- Start
- Jan 2024
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JS105 in breast cancer, endometrial cancer (EC), Cervical Cancer (CC), ovarian cancer, fallopian tube cancer (PFTC), sponsored by Risen Pharma. Started Jan 2024; status: recruiting.
02
Drugs
JS105
03
Conditions
breast cancerendometrial cancer (EC)Cervical Cancer (CC)ovarian cancerfallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT06208410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06208410.